Save up to 90% on Hemlibra with Coupons, Discount Cards & Patient Assistance Programs

Hemlibra is the brand name for emicizumab-kxwh subcutneous injection.

Hemlibra is available as a 30 mg/mL, 60 mg/0.4 mL, 105 mg/0.7 mL or 150 mg/mL single-dose vial.

Hemlibra is a monoclonal antibody that is used for the prevention of bleeding episodes in children and adults with hemophilia A.

Hemlibra is a monoclonal antibody that does the same job as factor VIII of bringing two important clotting factors together to continue the clotting process in the blood.

Your dose of Hemlibra depends on your weight. The typical starting dose is 3 mg/kg injected under the skin once weekly for the first 4 weeks. Your healthcare provider will have you continue with one of the following maintenance doses, depending on which is best for you:

• 1.5 mg/kg injected under the skin every week, OR
• 3 mg/kg injected under the skin every 2 weeks, OR
• 6 mg/kg injected under the skin every 4 weeks

Hemlibra is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Hemlibra:

• Injection site reaction (bruising, redness, pain, swelling)
• Headache
• Joint pain
• Diarrhea
• Fever

Serious side effects are rare with Hemlibra.

The following medications may interact with Hemlibra:

• Clinical experience suggests that a drug interaction exists with Hemlibra and aPCC. There is a possibility for an increased risk of clotting with rFVIIa or FVIII with Hemlibra based on preclinical experiments.

Genentech, Inc.

It is not known if Hemlibra may harm your unborn baby. Females who are able to become pregnant should use birth control (contraception) during treatment with Hemlibra.

• Emicizumab-KXWH